Guardant Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Guardant Health, Inc. on May 27, 2020, reporting events occurring on May 26, 2020. The filing details a significant executive compensation arrangement approved by the Board of Directors for the Company's founders, Helmy Eltoukhy (CEO) and AmirAli Talasaz (President and COO).
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the valuation of the new equity awards:
- Total Award Value Basis: $131,000,000 per founder.
- Grant Size: 1,695,574 Performance-Based Restricted Stock Units (PSUs) per founder.
- Valuation Method: Calculated by dividing the $131 million target value by the volume-weighted average stock price (VWAP) over the 180 days ending on the grant date.
Material Changes and Compensation Structure
The Board approved a long-term incentive plan designed to align founder interests with long-term stockholder value. Key structural changes include:
- Salary Reduction: Both founders agreed to reduce their annual base salary to $1 until the seventh anniversary of the grant date (May 26, 2027).
- Bonus Waiver: Founders waived eligibility for annual bonuses for 2020 and any period prior to the seventh anniversary of the grant.
- Equity Restriction: Founders agreed not to receive other equity-based or long-term incentive awards prior to calendar year 2027.
- First Grant Since IPO: These are the first equity awards granted to the founders since July 2017.
Outlook, Vesting Conditions, and Risks
The PSUs vest based on sustained stock price appreciation over a seven-year period. The filing outlines specific performance hurdles and risks:
- Vesting Triggers: One-third of the PSUs vest upon the stock price achieving and sustaining (for 30 consecutive days) $120, $150, or $200 per share.
- Expiration Risk: No PSUs will vest if the stock price does not attain $120 per share prior to the Expiration Date (May 26, 2027). Unvested PSUs automatically terminate on this date without consideration.
- Change in Control: Vesting accelerates partially or fully depending on the deal price relative to the grant date fair market value and the $120 threshold.
- Termination Provisions: Specific vesting rules apply for termination without cause, for good reason, death, or disability.
- Lock-Up Periods: Shares received upon vesting are subject to holding periods (one year for vesting within three years of grant; six months for vesting after four years).
Investor Verification Checklist
- Verify the current stock price relative to the $120, $150, and $200 vesting thresholds.
- Confirm the 180-day VWAP used to calculate the 1,695,574 PSU count.
- Review the full terms of the Performance-Based Restricted Stock Unit Agreement (Exhibit 10.1) for specific definitions of "sustained achievement" and "good reason."
- Monitor the Company's progress on the LUNAR programs, which are cited as a strategic focus for the founders.
- Assess the impact of the founders' $1 salary on the Company's reported operating expenses in future filings.